81 completed, 19 terminated, 7 withdrawn, 3 active not recruiting. 60 Phase 2, 39 Phase 1, 16 Not applicable, 7 Phase 3, 2 Early Phase 1.
Follow Stage IIIB Non-Small Cell Lung Cancer: new trials by email Literature Review of Stage IIIB Non-Small Cell Lung Cancer trials Research Report on Stage IIIB Non-Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC Circulating Tumor-Specific T Cell Nanodetection Technology (CTT-NanoDT) - Non-Small Cell Lung Cancer, Lung Adenocarcinoma | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 80 | 2026-04-01 | 2026-02-06 | |
| Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC Sintilimab, Paclitaxel, Carboplatin (AUC 5) - Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer | Phase 2 | Recruiting | Yang Hong | 28 | 2025-12-31 | 2026-04-30 |
| Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. Non Small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Recruiting | Gene Solutions | 50 | 2023-12-04 | 2025-07-16 | |
| Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer ONO-7475, Osimertinib Mesylate - Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 78 | 2021-08-06 | 2026-03-13 |
| Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) Carboplatin, Placlitaxel, Atezolizumab - Lung Diseases, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Fundación GECP | 38 | 2021-06-16 | 2026-07-22 |
| CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer Durvalumab, Surgery, Radiotherapy - Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Alliance Foundation Trials, LLC. | 38 | 2021-03-10 | 2026-09-23 |
| Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer ViewRay MR-Linear Accelerator, Radiation therapy, Paclitaxel - Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer | Phase 2 | Completed | Washington University School of Medicine | 26 | 2019-06-20 | 2026-10-06 |
| Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Naloxegol, Placebo, Laboratory Biomarker Analysis - Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 2 | Terminated | Alliance for Clinical Trials in Oncology | 50 | 2018-03-23 | 2025-07-17 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer | Phase 2 | Unknown | Northwestern University | 17 | 2017-07-12 | 2020-10-14 |
| Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer Laboratory Biomarker Analysis, Nimotuzumab, Nivolumab - EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma | Phase 1 | Completed | Roswell Park Cancer Institute | 7 | 2017-06-29 | 2023-10-05 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Completed | University of Southern California | 42 | 2017-03-10 | 2025-10-22 |
| TG4010 and Nivolumab in Patients With Lung Cancer TG4010, Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | Phase 2 | Completed | Megan Daly, MD | 13 | 2016-12-14 | 2025-11-10 |
| Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Carboplatin, Cisplatin, Palbociclib - Solid Neoplasm, Stage III Pancreatic Cancer | Phase 1 | Completed | Emory University | 71 | 2016-10-24 | 2023-10-10 |
| S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration - Febrile Neutropenia, Stage 0 Breast Cancer | Not applicable | Completed | SWOG Cancer Research Network | 3665 | 2016-10-07 | 2022-10-20 |
| Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer Laboratory Biomarker Analysis, Pembrolizumab - Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 11 | 2016-09-15 | 2021-07-14 |
| Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy - Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer | Phase 1 | Completed | Rutgers, The State University of New Jersey | 23 | 2016-08-04 | 2025-12-16 |
| Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 43 | 2016-06-17 | 2024-01-05 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-06-01 | 2017-04-24 | |
| Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography Dexamethasone, Device for PET, Laboratory Biomarker Analysis - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 6 | 2016-06-01 | 2025-08-22 |
Showing 20 of 115. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (115) · Adenocarcinoma of Lung (21) · Adenocarcinoma, Bronchiolo-Alveolar (12) · Pancreatic Neoplasms (10) · Breast Neoplasms (9) · Colonic Neoplasms (9) · Rectal Neoplasms (9) · Squamous Cell Carcinoma of Head and Neck (9) · Carcinoma, Renal Cell (7) · Small Cell Lung Carcinoma (7) · Pleural Effusion, Malignant (6) · Salivary Gland Neoplasms (6) · Breast Neoplasms, Male (5) · Carcinoma, Ovarian Epithelial (5) · Urinary Bladder Neoplasms (5)
Bronchial Neoplasms (115) · Neoplasms by Site (115) · Respiratory Tract Diseases (115) · Carcinoma, Bronchogenic (114) · Lung Diseases (114) · Respiratory Tract Neoplasms (114) · Thoracic Neoplasms (114) · Lung Neoplasms (112) · Neoplasms (112) · Neoplasms by Histologic Type (41) · Neoplasms, Glandular and Epithelial (39) · Carcinoma (38) · Adenocarcinoma (32) · Digestive System Diseases (15) · Digestive System Neoplasms (15)
Carboplatin (28) · Paclitaxel (27) · Taxes (21) · Erlotinib Hydrochloride (17) · Cisplatin (13) · Radiotherapy (11) · Gemcitabine (10) · Docetaxel (9) · Radiation (7) · Bevacizumab (6) · Bortezomib (6) · Radiotherapy, Conformal (6) · Etoposide (5) · Pemetrexed (5) · pembrolizumab (5)
National Cancer Institute (NCI) (51) · Roswell Park Cancer Institute (5) · University of Washington (4) · Wake Forest University Health Sciences (4) · Albert Einstein College of Medicine (3) · City of Hope Medical Center (3) · Ohio State University Comprehensive Cancer Center (3) · University of Southern California (3) · Barbara Ann Karmanos Cancer Institute (2) · Emory University (2) · Fox Chase Cancer Center (2) · Jonsson Comprehensive Cancer Center (2) · Mayo Clinic (2) · QLT Inc. (2) · Virginia Commonwealth University (2)
United States (98) · Canada (5) · China (2) · Israel (1) · Japan (1) · Puerto Rico (1) · Spain (1) · Vietnam (1)
Alex Adjei (6) · Angela Davies (2) · Chukwumere Nwogu (2) · Elisabeth Weiss, MD (2) · Julie Brahmer (2) · Karen Kelly (2) · Michael Kelley (2) · Miguel Villalona-Calero (2) · Shilpen Patel (2) · Shirish Gadgeel (2) · Agustin Garcia (1) · Alain Mita (1) · Alan Sandler (1) · Andrei M Iagaru, MD (1) · Angela Alistar (1)
PMID 17167137, PMID 22586682, PMID 23475103, PMID 24100924, PMID 24246704, PMID 25965900, PMID 26062933, PMID 26611425, PMID 28598227, PMID 29874546, PMID 30497431, PMID 30850872, PMID 32077891, PMID 34323922, PMID 34749008, PMID 35254001, PMID 35365139, PMID 35771552, PMID 36228177, PMID 36279134, PMID 37770704, PMID 37788414, PMID 38206614, PMID 40973049, PMID 41114938, PMID 41681846
N01CM62201 (6), U10CA032102 (6), N01CM62209 (5), U10CA025224 (5), U10CA021115 (4), U10CA031946 (4), N01CM62208 (3), P30CA013330 (3), U01CA076576 (3), N01CM17102 (2), N01CM62203 (2), P30CA006973 (2), P30CA012197 (2), P30CA014089 (2), P30CA014520 (2)